{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:41:58Z","timestamp":1792669318608,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"DOI":"10.1007\/s40265-026-02405-y","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:07:07Z","timestamp":1792667227000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small Molecules Prescribed On- and Off-Label for Thoracic Cancers During Pregnancy: A Combined VigiBase and Systematic Review Analysis"],"prefix":"10.1007","author":[{"given":"Roberta","family":"Noseda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Salfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bedussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Proietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Pedrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Brenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Tortola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Montelatici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Santi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Selleret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Froesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedro","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Scarfone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjust","family":"Florez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2521-7540","authenticated-orcid":false,"given":"Martina","family":"Imbimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"2405_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.annonc.2024.08.2336","volume":"35","author":"S Ogino","year":"2024","unstructured":"Ogino S, Ugai T. The global epidemic of early-onset cancer: nature, nurture, or both? Ann Oncol. 2024;35:1071\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2336.","journal-title":"Ann Oncol"},{"key":"2405_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1470-2045(18)30059-7","volume":"19","author":"J de Haan","year":"2018","unstructured":"de Haan J, Verheecke M, Van Calsteren K, Van Calster B, Shmakov RG, Mhallem Gziri M, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol. 2018;19:337\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(18)30059-7.","journal-title":"Lancet Oncol"},{"key":"2405_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaoncol.2023.0339","volume":"9","author":"ZF Cairncross","year":"2023","unstructured":"Cairncross ZF, Shack L, Nelson G, Friedenreich CM, Ray J, Fell DB, et al. Long-term mortality in individuals diagnosed with cancer during pregnancy or postpartum. JAMA Oncol. 2023;9:791. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0339.","journal-title":"JAMA Oncol"},{"key":"2405_CR4","doi-asserted-by":"publisher","DOI":"10.1089\/whr.2023.0085","author":"JP Zhou","year":"2023","unstructured":"Zhou JP, Wang Y, Lin YN, Sun XW, Ding YJ, Yan YR, et al. Clinical features and management of lung cancer during pregnancy: a narrative review based on reported cases. Women Health Rep (New Rochelle). 2023. https:\/\/doi.org\/10.1089\/whr.2023.0085.","journal-title":"Women Health Rep (New Rochelle)"},{"key":"2405_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1780320","author":"N Guevara Rodriguez","year":"2026","unstructured":"Guevara Rodriguez N, Coreas N, Olazagasti C, Imbimbo M, Florez N. Treating without guidelines: management and outcomes of lung cancer diagnosed during pregnancy\u2014a systematic review. Front Oncol. 2026. https:\/\/doi.org\/10.3389\/fonc.2026.1780320.","journal-title":"Front Oncol"},{"key":"2405_CR6","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.21037\/apm-20-999","volume":"9","author":"X Han","year":"2020","unstructured":"Han X, Yang H, Zhang Y, Ma X. Three cases of lung cancer in pregnancy and literature review. Ann Palliat Med. 2020;9:1928\u201336. https:\/\/doi.org\/10.21037\/apm-20-999.","journal-title":"Ann Palliat Med"},{"key":"2405_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/1520-6661(200011\/12)9:6<373::AID-MFM1012;3.0.CO;2-8","volume":"9","author":"PS Ramsey","year":"2000","unstructured":"Ramsey PS, Danilenko-Dixon DR, Ramin KD, Ogburn PL. Malignant pleural mesothelioma in pregnancy. J Matern Fetal Med. 2000;9:373\u20135. https:\/\/doi.org\/10.1002\/1520-6661(200011\/12)9:6%3c373::AID-MFM1012%3e3.0.CO;2-8.","journal-title":"J Matern Fetal Med"},{"key":"2405_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00006254-198404000-00002","volume":"39","author":"KF Argubright","year":"1984","unstructured":"Argubright KF, Mattox JH, Messer RH. Thymoma in pregnancy. Obstet Gynecol Surv. 1984;39:185\u201391. https:\/\/doi.org\/10.1097\/00006254-198404000-00002.","journal-title":"Obstet Gynecol Surv"},{"key":"2405_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jtho.2024.02.005","volume":"19","author":"FA Peccatori","year":"2024","unstructured":"Peccatori FA, Florez N, Imbimbo M. From approximation to precision: fertility and pregnancy questions in young patients with lung cancer. J Thorac Oncol. 2024;19:852\u20134. https:\/\/doi.org\/10.1016\/j.jtho.2024.02.005.","journal-title":"J Thorac Oncol"},{"key":"2405_CR10","doi-asserted-by":"publisher","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","volume":"24","author":"FA Peccatori","year":"2013","unstructured":"Peccatori FA, Azim HA, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi160\u201370. https:\/\/doi.org\/10.1093\/annonc\/mdt199.","journal-title":"Ann Oncol"},{"key":"2405_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100037","author":"K Sorouri","year":"2023","unstructured":"Sorouri K, Loren AW, Amant F, Partridge AH. Patient-centered care in the management of cancer during pregnancy. Am Soc Clin Oncol Educ Book. 2023. https:\/\/doi.org\/10.1200\/EDBK_100037.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2405_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432488","author":"JC Laguna","year":"2024","unstructured":"Laguna JC, Tagliamento M, Lambertini M, Hiznay J, Mezquita L. Tackling non\u2013small cell lung cancer in young adults: from risk factors and genetic susceptibility to lung cancer profile and outcomes. Am Soc Clin Oncol Educ Book. 2024. https:\/\/doi.org\/10.1200\/EDBK_432488.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2405_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02115","author":"AW Loren","year":"2025","unstructured":"Loren AW, Lacchetti C, Amant F, Cardonick EH, Carey LA, Christian N, et al. Management of cancer during pregnancy: ASCO guideline. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-25-02115.","journal-title":"J Clin Oncol"},{"key":"2405_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.05.692","author":"AT Shaw","year":"2026","unstructured":"Shaw AT, Solomon BJ, Felip E, Bauer TM, Liu G, Goto Y, et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study. Ann Oncol. 2026. https:\/\/doi.org\/10.1016\/j.annonc.2026.05.692.","journal-title":"Ann Oncol"},{"key":"2405_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","volume":"390","author":"Y-L Wu","year":"2024","unstructured":"Wu Y-L, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alectinib in resected ALK -positive non\u2013small-cell lung cancer. N Engl J Med. 2024;390:1265\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2310532.","journal-title":"N Engl J Med"},{"key":"2405_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Groh\u00e9 C, et al. Overall survival with osimertinib in resected EGFR -mutated NSCLC. N Engl J Med. 2023;389:137\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2304594.","journal-title":"N Engl J Med"},{"key":"2405_CR17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jtho.2024.01.003","volume":"19","author":"E Simons","year":"2024","unstructured":"Simons E, Camidge DR. Lung cancer oncogene-directed therapy, fertility, and pregnancy. J Thorac Oncol. 2024;19:866\u201376. https:\/\/doi.org\/10.1016\/j.jtho.2024.01.003.","journal-title":"J Thorac Oncol"},{"key":"2405_CR18","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.cllc.2022.11.003","volume":"24","author":"EA Simons","year":"2023","unstructured":"Simons EA, Patil T, Camidge DR. Pregnancy and pathways to motherhood in oncogene-driven lung cancer: a single institution experience. Clin Lung Cancer. 2023;24:e55\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2022.11.003.","journal-title":"Clin Lung Cancer"},{"key":"2405_CR19","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/cncr.35227","volume":"130","author":"N Florez","year":"2024","unstructured":"Florez N, Kaufman RA, Y\u00e1\u00f1ez\u2010Sarmiento A, Abioye O, Kiel LR. When the unimaginable happens: lung cancer diagnosis during pregnancy. Cancer. 2024;130:1905\u20139. https:\/\/doi.org\/10.1002\/cncr.35227.","journal-title":"Cancer"},{"key":"2405_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010173","volume":"15","author":"R Noseda","year":"2022","unstructured":"Noseda R, M\u00fcller L, Bedussi F, Fusaroli M, Raschi E, Ceschi A. Immune checkpoint inhibitors and pregnancy: analysis of the VigiBase\u00ae spontaneous reporting system. Cancers (Basel). 2022;15:173. https:\/\/doi.org\/10.3390\/cancers15010173.","journal-title":"Cancers (Basel)"},{"key":"2405_CR21","doi-asserted-by":"publisher","first-page":"e2339934","DOI":"10.1001\/jamanetworkopen.2023.39934","volume":"6","author":"P Gougis","year":"2023","unstructured":"Gougis P, Grandal B, Jochum F, Bihan K, Coussy F, Barraud S, et al. Treatments during pregnancy targeting ERBB2 and outcomes of pregnant individuals and newborns. JAMA Netw Open. 2023;6:e2339934. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.39934.","journal-title":"JAMA Netw Open"},{"key":"2405_CR22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/cpt.3730","volume":"118","author":"A Cabannes\u2010Hamy","year":"2025","unstructured":"Cabannes\u2010Hamy A, Kabirian R, Jochum F, Bihan K, Dumas E, Coussy F, et al. BCR\u202f:: ABL1 tyrosine kinase inhibitors during pregnancy, a disproportionality analysis of Vigibase. Clin Pharmacol Ther. 2025;118:705\u201314. https:\/\/doi.org\/10.1002\/cpt.3730.","journal-title":"Clin Pharmacol Ther"},{"key":"2405_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","volume":"15","author":"E Raschi","year":"2020","unstructured":"Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Target Oncol. 2020;15:449\u201366. https:\/\/doi.org\/10.1007\/s11523-020-00738-6.","journal-title":"Target Oncol"},{"key":"2405_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-025-01559-0","volume":"48","author":"L Sandberg","year":"2025","unstructured":"Sandberg L, Vidlin SH, K-P\u00e1pai L, Savage R, Raemaekers BC, Taavola-Gustafsson H, et al. Uncovering pregnancy exposures in pharmacovigilance case report databases: a comprehensive evaluation of the VigiBase pregnancy algorithm. Drug Saf. 2025;48:1103\u201318. https:\/\/doi.org\/10.1007\/s40264-025-01559-0.","journal-title":"Drug Saf"},{"key":"2405_CR25","doi-asserted-by":"publisher","first-page":"e1228","DOI":"10.1634\/theoncologist.2019-0250","volume":"24","author":"E Raschi","year":"2019","unstructured":"Raschi E, Antonazzo IC, La Placa M, Ardizzoni A, Poluzzi E, De Ponti F. Serious cutaneous toxicities with immune checkpoint inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. Oncologist. 2019;24:e1228\u201331. https:\/\/doi.org\/10.1634\/theoncologist.2019-0250.","journal-title":"Oncologist"},{"key":"2405_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057","author":"PM Cutroneo","year":"2024","unstructured":"Cutroneo PM, Sartori D, Tuccori M, Crisafulli S, Battini V, Carnovale C, et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul. 2024. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057.","journal-title":"Front Drug Saf Regul"},{"key":"2405_CR27","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40264-020-00957-w","volume":"43","author":"L Sandberg","year":"2020","unstructured":"Sandberg L, Taavola H, Aoki Y, Chandler R, Nor\u00e9n GN. Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase. Drug Saf. 2020;43:999\u20131009. https:\/\/doi.org\/10.1007\/s40264-020-00957-w.","journal-title":"Drug Saf"},{"key":"2405_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf. 2024;47:575\u201384. https:\/\/doi.org\/10.1007\/s40264-024-01421-9.","journal-title":"Drug Saf"},{"key":"2405_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.lungcan.2007.10.025","volume":"60","author":"A Zambelli","year":"2008","unstructured":"Zambelli A, Prada GAD, Fregoni V, Ponchio L, Sagrada P, Pavesi L. Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy. Lung Cancer. 2008;60:455\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2007.10.025.","journal-title":"Lung Cancer"},{"issue":"2","key":"2405_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.lungcan.2012.03.026","volume":"77","author":"G Rivas","year":"2012","unstructured":"Rivas G, Llin\u00e1s N, Bonilla C, Rubiano J, Cuello J, Arango N. Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma. Lung Cancer. 2012;77(2):469\u201372. https:\/\/doi.org\/10.1016\/j.lungcan.2012.03.026.","journal-title":"Lung Cancer"},{"key":"2405_CR31","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1001\/jamaoncol.2015.1300","volume":"1","author":"Y Ji","year":"2015","unstructured":"Ji Y, Schwartz J, Hartford A, Ramsey J, Phillips J, Verschraegen C. Successful treatment of non\u2013small cell lung cancer with erlotinib throughout pregnancy. JAMA Oncol. 2015;1:838. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1300.","journal-title":"JAMA Oncol"},{"key":"2405_CR32","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1111\/bcp.16120","volume":"90","author":"Y Aida","year":"2024","unstructured":"Aida Y, Ohgami M, Mukai Y, Matsuyama M, Obata\u2010Yasuoka M, Satoh T, et al. Pharmacokinetic study of erlotinib in a pregnant woman with advanced non\u2010small cell lung cancer and observation of the effects on the child growth. Br J Clin Pharmacol. 2024;90:2554\u201361. https:\/\/doi.org\/10.1111\/bcp.16120.","journal-title":"Br J Clin Pharmacol"},{"key":"2405_CR33","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.lungcan.2011.08.008","volume":"74","author":"C-H Lee","year":"2011","unstructured":"Lee C-H, Liam C-K, Pang Y-K, Chua K-T, Lim B-K, Lai N-L. Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure. Lung Cancer. 2011;74:349\u201351. https:\/\/doi.org\/10.1016\/j.lungcan.2011.08.008.","journal-title":"Lung Cancer"},{"key":"2405_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.lungcan.2014.06.003","volume":"85","author":"S Gil","year":"2014","unstructured":"Gil S, Goetgheluck J, Paci A, Broutin S, Friard S, Couderc LJ, et al. Efficacy and safety of gefitinib during pregnancy: case report and literature review. Lung Cancer. 2014;85:481\u20134. https:\/\/doi.org\/10.1016\/j.lungcan.2014.06.003.","journal-title":"Lung Cancer"},{"key":"2405_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.5005\/jp-journals-10006-1607","volume":"10","author":"SR Tandulwadkar","year":"2018","unstructured":"Tandulwadkar SR, Kochar DK, Giri VV, Nayak VK. Pulmonary adenocarcinoma in pregnancy: a challenging case. J South Asian Feder Obst Gyn. 2018;10:281\u20133. https:\/\/doi.org\/10.5005\/jp-journals-10006-1607.","journal-title":"J South Asian Feder Obst Gyn"},{"key":"2405_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108456","volume":"202","author":"M Messekher","year":"2025","unstructured":"Messekher M, Fuchs F, Badr M, Pujol J-L. Gefitinib for EGFR mutated lung adenocarcinoma during pregnancy: a case report with 5-year follow-up. Lung Cancer. 2025;202:108456. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108456.","journal-title":"Lung Cancer"},{"key":"2405_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1108124","author":"P Soberanis Pina","year":"2023","unstructured":"Soberanis Pina P, Lara-Mej\u00eda L, Matias-Cruz V, Barr\u00f3n F, Cardona AF, Raez LE, et al. Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1108124.","journal-title":"Front Oncol"},{"key":"2405_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.lungcan.2021.09.001","volume":"161","author":"A-S Boudy","year":"2021","unstructured":"Boudy A-S, Grausz N, Selleret L, Gligorov J, Thomassin-Naggara I, Touboul C, et al. Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma. Lung Cancer. 2021;161:68\u201375. https:\/\/doi.org\/10.1016\/j.lungcan.2021.09.001.","journal-title":"Lung Cancer"},{"key":"2405_CR39","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jtho.2021.02.005","volume":"16","author":"G Scarfone","year":"2021","unstructured":"Scarfone G, Fumagalli M, Imbimbo M, Ceruti T, Cribi\u00f9 FM, Di Loreto E, et al. First case report of pregnancy on alectinib in a woman with metastatic ALK-rearranged lung cancer: a case report. J Thorac Oncol. 2021;16:873\u20137. https:\/\/doi.org\/10.1016\/j.jtho.2021.02.005.","journal-title":"J Thorac Oncol"},{"key":"2405_CR40","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13640","volume":"25","author":"F De Smedt","year":"2022","unstructured":"De Smedt F, Dessy F, Carestia L, Baldin P, Nana F, Clapuyt P, et al. A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: a case report and review of the literature. Oncol Lett. 2022;25:54. https:\/\/doi.org\/10.3892\/ol.2022.13640.","journal-title":"Oncol Lett"},{"key":"2405_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107188","volume":"180","author":"M Shang","year":"2023","unstructured":"Shang M, Luo X, Wu J, Wang Z, Chen Q, Zhou Y. The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout pregnancy: a case report. Lung Cancer. 2023;180:107188. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107188.","journal-title":"Lung Cancer"},{"key":"2405_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100361","volume":"3","author":"C Weidenbaum","year":"2022","unstructured":"Weidenbaum C, Cann CG, Osmundson S, Iams WT, Osterman T. Two uncomplicated pregnancies on alectinib in a woman with metastatic ALK-rearranged NSCLC: a case report. JTO Clin Res Rep. 2022;3:100361. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100361.","journal-title":"JTO Clin Res Rep"},{"key":"2405_CR43","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/j.cllc.2023.11.006","volume":"25","author":"LF Gonzalez-Mosquera","year":"2024","unstructured":"Gonzalez-Mosquera LF, Rous FA, Rogers A, Smith N, Goyert G, Gadgeel S. ALK rearrangement positive lung adenocarcinoma in pregnancy treated with alectinib: a case report. Clin Lung Cancer. 2024;25:e77-80. https:\/\/doi.org\/10.1016\/j.cllc.2023.11.006.","journal-title":"Clin Lung Cancer"},{"key":"2405_CR44","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63592","author":"M Kato","year":"2024","unstructured":"Kato M, Yamaura T, Mine H, Kin S, Suzuki H. Anaplastic lymphoma kinase-tyrosine kinase inhibitor treatment for metastatic non-small cell lung cancer throughout the entire gestation period. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.63592.","journal-title":"Cureus"},{"key":"2405_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-255575","volume":"17","author":"F Wu","year":"2024","unstructured":"Wu F, Rittberg R, Lim K, Ho C. Treating anaplastic lymphoma kinase (ALK) fusion-driven metastatic non-small cell lung cancer (NSCLC) with alectinib through pregnancy. BMJ Case Rep. 2024;17:e255575. https:\/\/doi.org\/10.1136\/bcr-2023-255575.","journal-title":"BMJ Case Rep"},{"key":"2405_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/carm\/9032427","author":"N Yeo","year":"2025","unstructured":"Yeo N, Johnston F, Fay L, Lilburn P, Kennedy D, Barrett H, et al. Beating the odds: a successful pregnancy in a patient with ALK-rearranged lung cancer on alectinib. Case Rep Med. 2025. https:\/\/doi.org\/10.1155\/carm\/9032427.","journal-title":"Case Rep Med"},{"key":"2405_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.11.012","author":"R Pham","year":"2025","unstructured":"Pham R, Garama D, Malhotra A, Kwok A, Varshney S, Low L, et al. Brief report: alectinib with salvage platinum-taxane chemotherapy in a pregnant woman with ALK-rearranged NSCLC and rapid disease progression followed by a successful pregnancy. J Thorac Oncol. 2025. https:\/\/doi.org\/10.1016\/j.jtho.2025.11.012.","journal-title":"J Thorac Oncol"},{"key":"2405_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2023.102673","volume":"52","author":"M Mawet","year":"2023","unstructured":"Mawet M, Basse C, Barrois M, Gligorov J, Cadranel J, Chabbert-Buffet N, et al. Second-trimester medical abortion after exposure to lorlatinib during early pregnancy, a case report. J Gynecol Obstet Hum Reprod. 2023;52:102673. https:\/\/doi.org\/10.1016\/j.jogoh.2023.102673.","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2405_CR49","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.jtho.2025.05.017","volume":"20","author":"Z Yao","year":"2025","unstructured":"Yao Z, Tang M, Jin Y, Ruan J, Hu Y, Xie H, et al. Successful pregnancy and healthy baby outcome in a patient with tyrosine kinase inhibitor\u2013refractory ALK-positive NSCLC and central nervous system metastasis treated with lorlatinib with maternal-fetal pharmacokinetics and child milestone development correlations. J Thorac Oncol. 2025;20:1531\u20137. https:\/\/doi.org\/10.1016\/j.jtho.2025.05.017.","journal-title":"J Thorac Oncol"},{"key":"2405_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/0284186X.2018.1497302","volume":"58","author":"KH Jensen","year":"2019","unstructured":"Jensen KH, Persson G, Storgaard L, Nielsen BB, Pedersen BW, Maroun LL, et al. Antineoplastic treatment with crizotinib during pregnancy: a case report. Acta Oncol (Madr). 2019;58:121\u20132. https:\/\/doi.org\/10.1080\/0284186X.2018.1497302.","journal-title":"Acta Oncol (Madr)"},{"key":"2405_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1784859","author":"T Weber","year":"2026","unstructured":"Weber T, Hoffmann J, Michel C, Burchert A, Pesek J, Taudte RV, et al. Case report: pregnant ROS1+ lung cancer patient treated with crizotinib\u2014impact on infancy. Front Oncol. 2026. https:\/\/doi.org\/10.3389\/fonc.2026.1784859.","journal-title":"Front Oncol"},{"key":"2405_CR52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.pulmoe.2018.03.007","volume":"24","author":"E Padr\u00e3o","year":"2018","unstructured":"Padr\u00e3o E, Melo C, Fernandes G, Magalh\u00e3es A. Lung cancer in pregnancy \u2013 report of a case treated with crizotinib \u2606. Pulmonology. 2018;24:205\u20137. https:\/\/doi.org\/10.1016\/j.pulmoe.2018.03.007.","journal-title":"Pulmonology"},{"key":"2405_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-025-01119-9","volume":"32","author":"C Tito","year":"2025","unstructured":"Tito C, Masciarelli S, Colotti G, Fazi F. EGF receptor in organ development, tissue homeostasis and regeneration. J Biomed Sci. 2025;32:24. https:\/\/doi.org\/10.1186\/s12929-025-01119-9.","journal-title":"J Biomed Sci"},{"key":"2405_CR54","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1042\/BJ20090387","volume":"420","author":"RH Palmer","year":"2009","unstructured":"Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009;420:345\u201361. https:\/\/doi.org\/10.1042\/BJ20090387.","journal-title":"Biochem J"},{"key":"2405_CR55","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.placenta.2026.05.024","volume":"182","author":"L Benoit","year":"2026","unstructured":"Benoit L, Combarel D, Dieudonne M-N, Rodriguez Y, Heggarty E, Mir O, et al. Transplacental transfer of osimertinib and alectinib using an ex vivo human placental perfusion model. Placenta. 2026;182:116\u201322. https:\/\/doi.org\/10.1016\/j.placenta.2026.05.024.","journal-title":"Placenta"},{"key":"2405_CR56","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","volume":"27","author":"N Colclough","year":"2021","unstructured":"Colclough N, Chen K, Johnstr\u00f6m P, Strittmatter N, Yan Y, Wrigley GL, et al. Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res. 2021;27:189\u2013201. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1871.","journal-title":"Clin Cancer Res"},{"key":"2405_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40262-018-0689-7","volume":"58","author":"T Hirota","year":"2019","unstructured":"Hirota T, Muraki S, Ieiri I. Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Clin Pharmacokinet. 2019;58:403\u201320. https:\/\/doi.org\/10.1007\/s40262-018-0689-7.","journal-title":"Clin Pharmacokinet"},{"key":"2405_CR58","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"TW Johnson","year":"2014","unstructured":"Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57:4720\u201344. https:\/\/doi.org\/10.1021\/jm500261q.","journal-title":"J Med Chem"},{"key":"2405_CR59","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.tjog.2023.07.026","volume":"62","author":"PY-C Chai","year":"2023","unstructured":"Chai PY-C, Lin C, Kao C-C, Lin L-M, Chen Y-H, Sun C-Y. Use of everolimus following kidney transplantation during pregnancy: a case report and systematic review. Taiwan J Obstet Gynecol. 2023;62:774\u20138. https:\/\/doi.org\/10.1016\/j.tjog.2023.07.026.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"2405_CR60","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/aogs.14811","volume":"103","author":"EA Huis in \u2019t Veld","year":"2024","unstructured":"Huis in \u2019t Veld EA, Van Assche IA, Amant F. Long\u2010term outcomes of children after prenatal exposure to maternal cancer and its treatment. Acta Obstet Gynecol Scand. 2024;103:757\u201360. https:\/\/doi.org\/10.1111\/aogs.14811.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2405_CR61","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.annonc.2025.04.011","volume":"36","author":"EA Huis in \u2019t Veld","year":"2025","unstructured":"Huis in \u2019t Veld EA, Van Assche IA, Van Calsteren K, Salaets T, Slieker MG, Cardonick E, et al. Long-term development of 12- and 15-year-old offspring after maternal cancer diagnosis during pregnancy: a prospective multicentre cohort study. Ann Oncol. 2025;36:1025\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2025.04.011.","journal-title":"Ann Oncol"},{"key":"2405_CR62","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1508913","volume":"373","author":"F Amant","year":"2015","unstructured":"Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015;373:1824\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1508913.","journal-title":"N Engl J Med"},{"key":"2405_CR63","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/S0140-6736(25)01497-7","volume":"406","author":"L Moayad","year":"2025","unstructured":"Moayad L, Mihan A, Peters SAE, Van Spall HGC. Inclusion of women who are pregnant, lactating, or of reproductive potential in clinical trials: health, ethical, and regulatory considerations. Lancet. 2025;406:2858\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(25)01497-7.","journal-title":"Lancet"},{"key":"2405_CR64","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0862-7","volume":"22","author":"C Maggen","year":"2020","unstructured":"Maggen C, Wolters VERA, Cardonick E, Fumagalli M, Halaska MJ, Lok CAR, et al. Pregnancy and cancer: the INCIP project. Curr Oncol Rep. 2020;22:17. https:\/\/doi.org\/10.1007\/s11912-020-0862-7.","journal-title":"Curr Oncol Rep"},{"key":"2405_CR65","unstructured":"Advisory Board on Cancer, Infertility and Pregnancy (ABCIP). https:\/\/www.ab-cip.org\/. Accessed 01 2026."},{"key":"2405_CR66","unstructured":"R\u00e9seau Cancer Associ\u00e9 \u00e0 la Grossesse (CALG). https:\/\/cancer-grossesse.aphp.fr\/. Accessed 01 2026."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02405-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02405-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02405-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:07:09Z","timestamp":1792667229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02405-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":66,"alternative-id":["2405"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02405-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"11 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Giuseppe Salfi reports a travel grant by Bayer. Dr Martino Pedrani reports a travel grant by Bayer. Dr Marina C. Garassino reports personal financial relationships with the following pharmaceutical companies (consulting\/honoraria\/other personal fees): AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, IO Biotech, Janssen Pharmaceuticals, Merck & Co., Mirati Therapeutics, Natera, Novocure, Nuvation, Nuvalent, Pfizer, Regeneron, Revolution Medicines, Roche, Summit, and Takeda; and with the following non-pharma organisations: Aptitude Health, Astro, Ideology, Intellisphere, MJH Holding, Oncohost, and IASLC. Research grants\/funding have been received from AIRC, AIFA, the Italian Ministry of Health, TRANSCAN, Horizon 2020, and Fondazione Veronesi. All disclosures are outside the submitted work. Dr Jacques Cadranel reports personal financial relationships with the following pharmaceutical companies (consulting\/honoraria\/other personal fees): AMGEN, Astra Zeneca, Boehringer Ingelheim, Pfizer, Roche, Takeda. All disclosures are outside the submitted work. Dr Narjust Florez reports Advisory\/Consulting: Johnson & Johnson, Sanofi , Pfizer, Mirati, Bristol Myers Squibb, Merck, Regeneron, Takeda, Lilly, Daiichi Sankyo, EMD Serono, Novartis, Jazz Pharmaceuticals, Genentech-Roche, Nuvalent, Nuvation Bio, Catalyst Pharmaceuticals, Caris, and AstraZeneca. Research funding: American Society of Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASLC), Lungevity Foundation, Champa Fund for early cancer detection, GO2 Foundation for Lung Cancer, Women\u2019s Health Access Matters (WHAM) Foundation, Daiichi Sankyo, Genentech, AstraZeneca, Johnson & Johnson, and Pfizer. Speakers Engagement: Clinical Care Options (CCO), Dava Oncology, CME Outfitters, ASCO Post, OncLive, and Physician Education Resource (PER). All disclosures are outside the submitted work. Dr Patrizia Froesch reports Participation on a Data Safety Monitoring Board or Advisory Board: Roche, Janssen, Pfizer, Novartis, Lilly, Sanofi. Amgen, Pharmamar, BMS, MSD. All disclosures are outside the submitted work. Dr Martina Imbimbo reports personal financial relationships with the following pharmaceutical companies (consulting\/honoraria\/other personal fees): BMS, Roche, Pharmamar, Astra Zeneca, Anaveon, Immatics. All disclosures are outside the submitted work. Roberta Noseda, Francesca Bedussi, Manuela Proietto, Daniele Brenna, Luigi Tortola, Giulia Montelatici, Alessandro Santi, Lise Selleret, Alessandro Ceschi, Emanuel Raschi, Fedro Peccatori, and Giovanna Scarfone declare the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As data in VigiBase are anonymised, ethical approval was not required in accordance with the Swiss Human Research Act (HRA; Art. 2).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets analyzed during the current study are not publicly available because they are proprietary data held by the Uppsala Monitoring Centre and are subject to data access agreements and confidentiality requirements. Consequently, the data cannot be shared through a public repository. Access to the data may be requested directly from the Uppsala Monitoring Centre, subject to its data access policies and approval procedures.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The code used in this study is available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Roberta Noseda and Giuseppe Salfi contributed equally to this work and share first authorship. All authors contributed to the conceptualisation and methodology of the study. Roberta Noseda, Giuseppe Salfi, Francesca Bedussi, and Martina Imbimbo contributed to data collection, curation, and analysis. Roberta Noseda, Giuseppe Salfi and Martina Imbimbo drafted the manuscript. All the other authors contributed to the interpretation of the findings and critically reviewed the manuscript. Martina Imbimbo supervised the study. All authors read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI tools were used to improve the English language and readability of the manuscript. The implementation was done with human oversight and control and authors carefully reviewed and edited the result. The authors are ultimately responsible and accountable for the contents of the work.","order":8,"name":"Ethics","label":"AI Use","group":{"name":"EthicsHeading","label":"Declarations"}}]}}